Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Lung Neoplasms 2Liver Neoplasms 2Hemangiosarcoma 2Glioma 2Choriocarcinoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Trophoblastic Tumor, Placental Site 1Sarcoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Gliosarcoma 1Gestational Trophoblastic Disease 1Fallopian Tube Neoplasms 1Disease Progression 1Carcinoma, Transitional Cell 1Brain Neoplasms 1Astrocytoma 1Adult Solid Tumor 1Adenoma, Liver Cell 1

Interventions

Lenalidomide 4Gemcitabine 4Dexamethasone 4Cyclophosphamide 4Bortezomib 4Nivolumab 3Cisplatin 3Carboplatin 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2pomalidomide 2pembrolizumab 2liposomal doxorubicin 2fludarabine 2durvalumab 2capivasertib 2Paclitaxel 2Doxorubicin 2Bevacizumab 2venetoclax 1umbralisib 1ublituximab 1tremelimumab 1tivozanib 1ricolinostat 1regorafenib 1pazopanib 1niraparib 1nilotinib 1neratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Disease Progression × carotuximab × Clear all
NCT01778530 2015-10-07

TRC105 for Recurrent Glioblastoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 9 charts
CNS

Glioblastoma, Glioma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡